Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 421-425

  Kobayashi, Hiroyuki ^a,b   Morita, Keiko ^c   Takeshi, Kiyoaki ^c   Koshikawa, Hiroki ^d   Yamazawa, Ryoko ^a   Kashima, Haruo ^a   Mizuno, Masafumi ^c  

^a KEIO UNIVERSITY   (Japan)

^b Tokyo Musashino Hospital   (Japan)

^c TOHO UNIVERSITY   (Japan)

^d Shakujii Kouen Clinic   (Japan)

Author keywords

At risk mental state; Insight; Prodrome; Psychosis; Subjective experience

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MALE; MENTAL HEALTH; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCORING SYSTEM; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RISK FACTORS; THINKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349663683     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b2fe22     Document Type: Article

References (29)

1. Kane JM, Krystal J, Correll CU. Treatment models and designs for intervention research during the psychotic prodrome. Schizophr Bull. 2003;29:747-756.
2. Simon AE, Ferrero FP, Merlo MC. Prodromes of first-episode psychosis: how can we challenge nonspecificity? Compr Psychiatry. 2001;42:382-392.
3. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
4. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Randomized controlled trial. Br J Psychiatry. 2004;185:291-297.
5. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized double-blind clinical trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163:790-799.
6. Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine adverse events. J Am Acad Child Adolesc Psychiatry. 2002;41:1435-1446.
7. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68:546-557.
8. Ruhrmann S, Bechdolf A, Kuhn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry. 2007;191(suppl 51): 88-95.
9. Woods SW, Tully EM, Walsh BC, et al. Aripiprazole in the treatment of the psychosis prodrome. An open-label pilot study. Br J Psychiatry. 2007;191(suppl 51):96-101.
10. Lappin JM, Morgan KD, Valmaggia LR, et al. Insight in individuals with an at risk mental state. Schizophr Res. 2007;90:238-244.
11. David A, van Os J, Jones P, et al. Insight and psychotic illness: cross-sectional and longitudinal associations. Br J Psychiatry. 1995;167:621-628.
12. Smith TE, Hull JW, Goodman M, et al. The relative influences of symptoms, insight and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999;187:102-108.
13. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75-80.
14. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Pschiatr Scand Suppl. 2005;427:29-34.
15. Garavan J, Browne S, Grevin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215-219.
16. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29: 703-715.
17. Kobayashi H, Nozaki S, Mizuno M. Reliability of the Structured Interview for Prodromal Syndromes Japanese version (SIPS-J). Jpn Soc Psychiat. 2005;15:168-174. Japanese.
18. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
19. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
20. Watanabe M, Matsumura H. Reliability and validity of Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J). Jpn J Clin Psychopharmacology. 2003;6:905-912. [in Japanese].
21. Amador XF, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873-879.
22. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
23. Lecomte T, Spidel A, Leclerc C, et al. Predictors and profiles of treatment non-adherence and engagement in services problems in early psychosis. Schizophr Res. 2008;102:295-302.
24. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
25. Keshavan MS, Rabinowitz J, DeSmedt G, et al. Correlates of insight in first episode psychosis. Schizophr Res. 2004;70:187-194.
26. Saeedi H, Addington J, Addington D. The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophr Res. 2007;89:123-128.
27. Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res. 2003;60:71-80.
28. Karow A, Pajonk FG, Reimer J, et al. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2008;258: 152-159.
29. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20.